CR10498A - Compuestos que tienen actividad en el transportador glyt1 - Google Patents

Compuestos que tienen actividad en el transportador glyt1

Info

Publication number
CR10498A
CR10498A CR10498A CR10498A CR10498A CR 10498 A CR10498 A CR 10498A CR 10498 A CR10498 A CR 10498A CR 10498 A CR10498 A CR 10498A CR 10498 A CR10498 A CR 10498A
Authority
CR
Costa Rica
Prior art keywords
glyt1
conveyor
activity
compounds
benzamide
Prior art date
Application number
CR10498A
Other languages
English (en)
Inventor
Clare Louise Anderton
David Clapham
Trevor Raymond Keel
Leanda Jane Kindon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10498A publication Critical patent/CR10498A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen sales de succinato y napadisilato y solvatos de napadisilato de 2-(metiloxi)-N-[2-meitl-1-fenil-2-(1-pirrolidinil)propil]-4,6-bis(trifluorometil)benzamida,6-bis(trifluorometil)benzamida, y sus usos en el tratamiento de trastornos referidos a los transportadores de GLyT1, tales como esquizofrenia.
CR10498A 2006-06-22 2008-12-11 Compuestos que tienen actividad en el transportador glyt1 CR10498A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612420.0A GB0612420D0 (en) 2006-06-22 2006-06-22 Compounds

Publications (1)

Publication Number Publication Date
CR10498A true CR10498A (es) 2009-03-20

Family

ID=36803732

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10498A CR10498A (es) 2006-06-22 2008-12-11 Compuestos que tienen actividad en el transportador glyt1

Country Status (23)

Country Link
US (1) US20080070973A1 (es)
EP (1) EP2041082B1 (es)
JP (1) JP2009541261A (es)
KR (1) KR20090019847A (es)
CN (1) CN101506156A (es)
AR (1) AR061554A1 (es)
AT (1) ATE444288T1 (es)
AU (1) AU2007263058A1 (es)
BR (1) BRPI0713311A2 (es)
CA (1) CA2655399A1 (es)
CL (1) CL2007001808A1 (es)
CR (1) CR10498A (es)
DE (1) DE602007002642D1 (es)
EA (1) EA200970044A1 (es)
ES (1) ES2333918T3 (es)
GB (1) GB0612420D0 (es)
IL (1) IL195633A0 (es)
MA (1) MA30522B1 (es)
NO (1) NO20085412L (es)
PE (1) PE20080380A1 (es)
TW (1) TW200817322A (es)
WO (1) WO2007147831A1 (es)
ZA (1) ZA200810009B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
US20100184996A1 (en) * 2007-06-20 2010-07-22 Glaxo Group Limited Process of amide formation
SG186885A1 (en) 2010-06-04 2013-02-28 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
KR20200071090A (ko) 2017-10-13 2020-06-18 트리웨이 티더블유001 비.브이. 에다라본 염

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746959A (en) * 1953-06-02 1956-05-22 American Home Prod Diphenylethylenediamine-penicillin salt
US3145209A (en) * 1961-07-31 1964-08-18 Olin Mathieson Substituted aminophenyl-ethylamine derivatives
NZ237443A (en) * 1990-04-10 1993-11-25 Asta Medica Ag Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina

Also Published As

Publication number Publication date
IL195633A0 (en) 2009-09-01
US20080070973A1 (en) 2008-03-20
AU2007263058A1 (en) 2007-12-27
ATE444288T1 (de) 2009-10-15
PE20080380A1 (es) 2008-05-31
KR20090019847A (ko) 2009-02-25
ZA200810009B (en) 2009-11-25
JP2009541261A (ja) 2009-11-26
EP2041082B1 (en) 2009-09-30
BRPI0713311A2 (pt) 2012-03-06
EA200970044A1 (ru) 2009-04-28
WO2007147831A1 (en) 2007-12-27
CL2007001808A1 (es) 2008-01-18
GB0612420D0 (en) 2006-08-02
MA30522B1 (fr) 2009-06-01
NO20085412L (no) 2009-01-22
AR061554A1 (es) 2008-09-03
TW200817322A (en) 2008-04-16
EP2041082A1 (en) 2009-04-01
CN101506156A (zh) 2009-08-12
ES2333918T3 (es) 2010-03-02
CA2655399A1 (en) 2007-12-27
DE602007002642D1 (de) 2009-11-12

Similar Documents

Publication Publication Date Title
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
UY32391A (es) Compuestos amino-heterocíclicos
BR112014004631A2 (pt) derivados de heterociclo bicíclico para o tratamento de hipertensão arterial pulmonar
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
DOP2014000230A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
NI200900204A (es) COMPUESTOS AMINO-HETEROCÍCLICOS. Caso: PC 33468A
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
SV2011003855A (es) Heteroarilos sustituidos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CR20130487A (es) 1,3-oxazinas como inhibidores de BACE1 y/o BACE2
DOP2010000234A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
NI201400120A (es) Inhibidores de diacilglicerol aciltransferasa 2
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
UY31243A1 (es) Compuestos de 2-aza-biciclo[2.2.2]octano y usos para los mismos
BRPI0818348A2 (pt) Derivados de n-(pirazol-3-il)-benzamida como ativadores de glicocinase
UY30835A1 (es) 8-alquinilxantinas y derivados
CR20140553A (es) Compuestos de fenoxietil piperidina
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
NI201500050A (es) Benzamidas
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
IT1397247B1 (it) Nuovi agenti regolatori dell'attivita' citochinica
CR10498A (es) Compuestos que tienen actividad en el transportador glyt1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)